JP2007510649A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510649A5 JP2007510649A5 JP2006538342A JP2006538342A JP2007510649A5 JP 2007510649 A5 JP2007510649 A5 JP 2007510649A5 JP 2006538342 A JP2006538342 A JP 2006538342A JP 2006538342 A JP2006538342 A JP 2006538342A JP 2007510649 A5 JP2007510649 A5 JP 2007510649A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- dichlorophenyl
- oxo
- alkyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 125000001424 substituent group Chemical group 0.000 claims description 44
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 229910052717 sulfur Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Chemical group 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims 33
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- -1 cycloheteroalkyl Chemical group 0.000 claims 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 11
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 208000008589 Obesity Diseases 0.000 claims 9
- 235000020824 obesity Nutrition 0.000 claims 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 8
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 235000014632 disordered eating Nutrition 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000037406 food intake Effects 0.000 claims 4
- 235000012631 food intake Nutrition 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010019196 Head injury Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 2
- 206010029333 Neurosis Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- KCVKRVYHRWLRHU-UHFFFAOYSA-N n-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]-2-hydroxyacetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)CO)=C(Cl)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl KCVKRVYHRWLRHU-UHFFFAOYSA-N 0.000 claims 2
- BBZWVTBKTBOJCP-UHFFFAOYSA-N n-[3-chloro-7-(2-chlorophenyl)-6-(4-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(Cl)C(=O)N(CC(C)C)C2=NC=1C1=CC=CC=C1Cl BBZWVTBKTBOJCP-UHFFFAOYSA-N 0.000 claims 2
- 230000003959 neuroinflammation Effects 0.000 claims 2
- 208000015238 neurotic disease Diseases 0.000 claims 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- ILFIRBGRMCGNOO-UHFFFAOYSA-N 1,1-bis($l^{1}-oxidanyl)ethene Chemical group [O]C([O])=C ILFIRBGRMCGNOO-UHFFFAOYSA-N 0.000 claims 1
- MZWWIXVQISOINP-UHFFFAOYSA-N 1-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]-1-ethylurea Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N(C(N)=O)CC)=C(C)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl MZWWIXVQISOINP-UHFFFAOYSA-N 0.000 claims 1
- HADBQKHAJJUBNI-UHFFFAOYSA-N 1-acetyl-8-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-hydroxy-5-methylpyrrolo[3,2-c][1,8]naphthyridin-4-one Chemical compound CC(=O)N1C=C(O)C(C(N(C)C2=NC=3C=4C(=CC(Cl)=CC=4)Cl)=O)=C1C2=CC=3C1=CC=C(Cl)C=C1 HADBQKHAJJUBNI-UHFFFAOYSA-N 0.000 claims 1
- JQHCPBMMQDCZQX-UHFFFAOYSA-N 3-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]-1,1-dimethylurea Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)N(C)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl JQHCPBMMQDCZQX-UHFFFAOYSA-N 0.000 claims 1
- YGZYHNDUHBNOTF-UHFFFAOYSA-N 3-acetyl-4-(benzylamino)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2-one Chemical compound C12=CC(C=3C=CC(Cl)=CC=3)=C(C=3C(=CC(Cl)=CC=3)Cl)N=C2N(C)C(=O)C(C(=O)C)=C1NCC1=CC=CC=C1 YGZYHNDUHBNOTF-UHFFFAOYSA-N 0.000 claims 1
- PCAFDAFQSCZHCE-UHFFFAOYSA-N 3-acetyl-4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(=O)C)=C(N)C2=CC=1C1=CC=C(Cl)C=C1 PCAFDAFQSCZHCE-UHFFFAOYSA-N 0.000 claims 1
- UWQVZDDDOKWIOS-UHFFFAOYSA-N 3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-4-(dimethylamino)-1-methyl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N(C)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl UWQVZDDDOKWIOS-UHFFFAOYSA-N 0.000 claims 1
- XXCJXONXIYYNBA-UHFFFAOYSA-N 3-benzyl-9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-2,4,6-trimethyl-4h-pyrimido[5,4-c][1,8]naphthyridin-5-one Chemical compound CC1=NC(C2=CC(=C(C=3C(=CC(Cl)=CC=3)Cl)N=C2N(C)C2=O)C=3C=CC(Cl)=CC=3)=C2C(C)N1CC1=CC=CC=C1 XXCJXONXIYYNBA-UHFFFAOYSA-N 0.000 claims 1
- HJIXRWARJSWUHW-UHFFFAOYSA-N 4-amino-3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-methylpropyl)-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N)=C(Cl)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl HJIXRWARJSWUHW-UHFFFAOYSA-N 0.000 claims 1
- URFSFUPWAUZWFZ-UHFFFAOYSA-N 4-amino-3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N)=C(Cl)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl URFSFUPWAUZWFZ-UHFFFAOYSA-N 0.000 claims 1
- FQQFAMJRHUONIR-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1,3-dimethyl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C)=C(N)C2=CC=1C1=CC=C(Cl)C=C1 FQQFAMJRHUONIR-UHFFFAOYSA-N 0.000 claims 1
- UAEFGCKKHDXZMC-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N)=CC(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl UAEFGCKKHDXZMC-UHFFFAOYSA-N 0.000 claims 1
- ZNDWJYNHAFALOQ-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridine-3-carbonitrile Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N)=C(C#N)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl ZNDWJYNHAFALOQ-UHFFFAOYSA-N 0.000 claims 1
- FZFRQXFLZNPSJU-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N)=C(C(N)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl FZFRQXFLZNPSJU-UHFFFAOYSA-N 0.000 claims 1
- HGRLDBZTMGLWKV-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-3-[methyl(propan-2-yl)amino]-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(N(C)C(C)C)=C(N)C2=CC=1C1=CC=C(Cl)C=C1 HGRLDBZTMGLWKV-UHFFFAOYSA-N 0.000 claims 1
- AIORRETVZIIHCL-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-3-propan-2-yl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(C)C)=C(N)C2=CC=1C1=CC=C(Cl)C=C1 AIORRETVZIIHCL-UHFFFAOYSA-N 0.000 claims 1
- FMAWDYWAOSGFLO-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(1-methoxyethyl)-1-methyl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(C)OC)=C(N)C2=CC=1C1=CC=C(Cl)C=C1 FMAWDYWAOSGFLO-UHFFFAOYSA-N 0.000 claims 1
- GSIBKPQAWLWLTH-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(dimethylamino)-1-methyl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(N(C)C)=C(N)C2=CC=1C1=CC=C(Cl)C=C1 GSIBKPQAWLWLTH-UHFFFAOYSA-N 0.000 claims 1
- NWXNPSNMKGHLDM-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-methyl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(CC)=C(N)C2=CC=1C1=CC=C(Cl)C=C1 NWXNPSNMKGHLDM-UHFFFAOYSA-N 0.000 claims 1
- VNDNPCXIAXSKMY-UHFFFAOYSA-N 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-1-(2-methylpropyl)-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N)=C(C)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl VNDNPCXIAXSKMY-UHFFFAOYSA-N 0.000 claims 1
- RAGXLLNOYVIGEP-UHFFFAOYSA-N 6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-4-(methylamino)-3-propan-2-yl-1,8-naphthyridin-2-one Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC)=C(C(C)C)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl RAGXLLNOYVIGEP-UHFFFAOYSA-N 0.000 claims 1
- DYRRONPLTLNJGZ-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-2,4,4,6-tetramethyl-[1,3]oxazino[5,4-c][1,8]naphthyridin-5-one Chemical compound CC1(C)OC(C)=NC(C2=CC=3C=4C=CC(Cl)=CC=4)=C1C(=O)N(C)C2=NC=3C1=CC=C(Cl)C=C1Cl DYRRONPLTLNJGZ-UHFFFAOYSA-N 0.000 claims 1
- SDGLFXVDRAAZLX-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-2,4,6-trimethyl-4h-[1,3]oxazino[5,4-c][1,8]naphthyridin-5-one Chemical compound CC1OC(C)=NC(C2=CC=3C=4C=CC(Cl)=CC=4)=C1C(=O)N(C)C2=NC=3C1=CC=C(Cl)C=C1Cl SDGLFXVDRAAZLX-UHFFFAOYSA-N 0.000 claims 1
- MMLRVSZLGSIZHT-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(2,4-dichlorophenyl)-2,6-dimethyl-3-propan-2-ylpyrimido[5,4-c][1,8]naphthyridine-4,5-dione Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C=3C(=O)N(C(C)C)C(C)=NC=3C2=CC=1C1=CC=C(Cl)C=C1 MMLRVSZLGSIZHT-UHFFFAOYSA-N 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 239000005973 Carvone Substances 0.000 claims 1
- 208000010235 Food Addiction Diseases 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- KATUZJCKXVLLOR-UHFFFAOYSA-N ethyl 4-amino-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridine-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(=O)OCC)=C(N)C2=CC=1C1=CC=C(Cl)C=C1 KATUZJCKXVLLOR-UHFFFAOYSA-N 0.000 claims 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 1
- 125000006178 methyl benzyl group Chemical group 0.000 claims 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
- OVUDXRNHXKJIOZ-UHFFFAOYSA-N n'-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]-n,n-dimethylmethanimidamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N=CN(C)C)=C(Cl)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl OVUDXRNHXKJIOZ-UHFFFAOYSA-N 0.000 claims 1
- FTXUOXNAIIXLSD-UHFFFAOYSA-N n'-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]-n,n-dimethylmethanimidamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(CC(C)C)C(=O)C(CC)=C(N=CN(C)C)C2=CC=1C1=CC=C(Cl)C=C1 FTXUOXNAIIXLSD-UHFFFAOYSA-N 0.000 claims 1
- FIMUVHASRJIHRJ-UHFFFAOYSA-N n'-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methoxy-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]-n,n-dimethylmethanimidamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(CC(C)C)C(=O)C(OC)=C(N=CN(C)C)C2=CC=1C1=CC=C(Cl)C=C1 FIMUVHASRJIHRJ-UHFFFAOYSA-N 0.000 claims 1
- BVJVWRBKDJHTKU-UHFFFAOYSA-N n'-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]-n,n-dimethylmethanimidamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N=CN(C)C)=C(C)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl BVJVWRBKDJHTKU-UHFFFAOYSA-N 0.000 claims 1
- PPIIUDQSAOROOZ-UHFFFAOYSA-N n-[3-acetyl-1-benzyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C12=NC(C=3C(=CC(Cl)=CC=3)Cl)=C(C=3C=CC(Cl)=CC=3)C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N1CC1=CC=CC=C1 PPIIUDQSAOROOZ-UHFFFAOYSA-N 0.000 claims 1
- RCHUBAICSBOPGM-UHFFFAOYSA-N n-[3-acetyl-1-butyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(C(C)=O)C(=O)N(CCCC)C2=NC=1C1=CC=C(Cl)C=C1Cl RCHUBAICSBOPGM-UHFFFAOYSA-N 0.000 claims 1
- UOBINQGZVYJCEQ-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-1-(cyclopropylmethyl)-7-(2,4-dichlorophenyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C12=NC(C=3C(=CC(Cl)=CC=3)Cl)=C(C=3C=CC(Cl)=CC=3)C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N1CC1CC1 UOBINQGZVYJCEQ-UHFFFAOYSA-N 0.000 claims 1
- JOSUFAGDYSRBJW-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-hydroxyethyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(CCO)C2=NC=1C1=CC=C(Cl)C=C1Cl JOSUFAGDYSRBJW-UHFFFAOYSA-N 0.000 claims 1
- FBTJXTNIWICRLD-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-methoxyethyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(C(C)=O)C(=O)N(CCOC)C2=NC=1C1=CC=C(Cl)C=C1Cl FBTJXTNIWICRLD-UHFFFAOYSA-N 0.000 claims 1
- JBQWPLWSNHELFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(C(C)=O)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl JBQWPLWSNHELFT-UHFFFAOYSA-N 0.000 claims 1
- VKROUWOXZUXJAU-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-[(2,4-dimethoxyphenyl)methyl]-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)C(C(C)=O)=C(NC(C)=O)C2=CC(C=3C=CC(Cl)=CC=3)=C(C=3C(=CC(Cl)=CC=3)Cl)N=C21 VKROUWOXZUXJAU-UHFFFAOYSA-N 0.000 claims 1
- FSRLMDODJVONGQ-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-ethyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(C(C)=O)C(=O)N(CC)C2=NC=1C1=CC=C(Cl)C=C1Cl FSRLMDODJVONGQ-UHFFFAOYSA-N 0.000 claims 1
- XNWFTRFDCMFMOB-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]-2-hydroxyacetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(=O)C)=C(NC(=O)CO)C2=CC=1C1=CC=C(Cl)C=C1 XNWFTRFDCMFMOB-UHFFFAOYSA-N 0.000 claims 1
- OUGDMJNQRYKRBR-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]-2-methoxyacetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)COC)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl OUGDMJNQRYKRBR-UHFFFAOYSA-N 0.000 claims 1
- JPSQRURXFPIHIK-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]-n-methylacetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N(C(C)=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl JPSQRURXFPIHIK-UHFFFAOYSA-N 0.000 claims 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 claims 1
- HSEQWGUPLOFKEC-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]methanesulfonamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(=O)C)=C(NS(C)(=O)=O)C2=CC=1C1=CC=C(Cl)C=C1 HSEQWGUPLOFKEC-UHFFFAOYSA-N 0.000 claims 1
- IRUIMNBPEZGQNR-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1-(oxolan-2-ylmethyl)-1,8-naphthyridin-4-yl]acetamide Chemical compound C12=NC(C=3C(=CC(Cl)=CC=3)Cl)=C(C=3C=CC(Cl)=CC=3)C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N1CC1CCCO1 IRUIMNBPEZGQNR-UHFFFAOYSA-N 0.000 claims 1
- CQPBAWWXYTUGNK-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1-(pyridin-1-ium-2-ylmethyl)-1,8-naphthyridin-4-yl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C12=NC(C=3C(=CC(Cl)=CC=3)Cl)=C(C=3C=CC(Cl)=CC=3)C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N1CC1=CC=CC=[NH+]1 CQPBAWWXYTUGNK-UHFFFAOYSA-N 0.000 claims 1
- XAJGHNNCBATXMR-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1-(pyridin-1-ium-3-ylmethyl)-1,8-naphthyridin-4-yl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C12=NC(C=3C(=CC(Cl)=CC=3)Cl)=C(C=3C=CC(Cl)=CC=3)C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N1CC1=CC=C[NH+]=C1 XAJGHNNCBATXMR-UHFFFAOYSA-N 0.000 claims 1
- BCTNKYVQPHJCSE-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1-(pyridin-1-ium-4-ylmethyl)-1,8-naphthyridin-4-yl]acetamide;2,2,2-trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.C12=NC(C=3C(=CC(Cl)=CC=3)Cl)=C(C=3C=CC(Cl)=CC=3)C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N1CC1=CC=[NH+]C=C1 BCTNKYVQPHJCSE-UHFFFAOYSA-N 0.000 claims 1
- XGQMSIBVABNZLK-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1-propyl-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(C(C)=O)C(=O)N(CCC)C2=NC=1C1=CC=C(Cl)C=C1Cl XGQMSIBVABNZLK-UHFFFAOYSA-N 0.000 claims 1
- PUNSHQSKVLQETC-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2-oxo-1h-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)NC2=NC=1C1=CC=C(Cl)C=C1Cl PUNSHQSKVLQETC-UHFFFAOYSA-N 0.000 claims 1
- ARIPOJIWKXKZGI-UHFFFAOYSA-N n-[3-acetyl-7-(2,4-dichlorophenyl)-1-methyl-6-(4-methylphenyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(C)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl ARIPOJIWKXKZGI-UHFFFAOYSA-N 0.000 claims 1
- HBEIAKQHWYVVFP-UHFFFAOYSA-N n-[3-acetyl-7-(2-chlorophenyl)-6-(4-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(C(C)=O)C(=O)N(CC(C)C)C2=NC=1C1=CC=CC=C1Cl HBEIAKQHWYVVFP-UHFFFAOYSA-N 0.000 claims 1
- KDOWZBWMIRYCEX-UHFFFAOYSA-N n-[3-acetyl-7-(2-chlorophenyl)-6-(4-chlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=CC=C1Cl KDOWZBWMIRYCEX-UHFFFAOYSA-N 0.000 claims 1
- BFIZQGWNCSXAEE-UHFFFAOYSA-N n-[3-acetyl-7-(4-chlorophenyl)-6-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1 BFIZQGWNCSXAEE-UHFFFAOYSA-N 0.000 claims 1
- HKVMTZWUKNCDJT-UHFFFAOYSA-N n-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(Cl)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl HKVMTZWUKNCDJT-UHFFFAOYSA-N 0.000 claims 1
- XWUORYRWSKPKFK-UHFFFAOYSA-N n-[3-chloro-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(Cl)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl XWUORYRWSKPKFK-UHFFFAOYSA-N 0.000 claims 1
- PAHFXNBVSLJKMB-UHFFFAOYSA-N n-[3-chloro-7-(2-chloro-4-fluorophenyl)-6-(4-chlorophenyl)-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(Cl)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(F)C=C1Cl PAHFXNBVSLJKMB-UHFFFAOYSA-N 0.000 claims 1
- WUKAECDVNMFOSF-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-3-cyano-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C#N)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl WUKAECDVNMFOSF-UHFFFAOYSA-N 0.000 claims 1
- MHXCSCGWSMXWKK-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1,3-dimethyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl MHXCSCGWSMXWKK-UHFFFAOYSA-N 0.000 claims 1
- OYBZCIMJVFORJO-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1,3-dimethyl-2-oxo-1,8-naphthyridin-4-yl]propanamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)CC)=C(C)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl OYBZCIMJVFORJO-UHFFFAOYSA-N 0.000 claims 1
- AAIQXNZXWNXHSX-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=CC(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl AAIQXNZXWNXHSX-UHFFFAOYSA-N 0.000 claims 1
- RNMRJQUHDLMTCB-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-3-propan-2-yl-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(C)C)=C(NC(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 RNMRJQUHDLMTCB-UHFFFAOYSA-N 0.000 claims 1
- AHBJMSWBVKIWEY-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-3-pyrrolidin-1-yl-1,8-naphthyridin-4-yl]acetamide Chemical compound O=C1N(C)C2=NC(C=3C(=CC(Cl)=CC=3)Cl)=C(C=3C=CC(Cl)=CC=3)C=C2C(NC(=O)C)=C1N1CCCC1 AHBJMSWBVKIWEY-UHFFFAOYSA-N 0.000 claims 1
- LWRKRCIWUJZVFY-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-3-[methyl(propan-2-yl)amino]-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(N(C)C(C)C)=C(NC(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 LWRKRCIWUJZVFY-UHFFFAOYSA-N 0.000 claims 1
- WEJZRLMFYOHWOU-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(1-hydroxyethyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(O)C)=C(NC(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 WEJZRLMFYOHWOU-UHFFFAOYSA-N 0.000 claims 1
- ODGHJZNJJZSEDF-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(1-methoxyethyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(C(C)OC)=C(NC(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 ODGHJZNJJZSEDF-UHFFFAOYSA-N 0.000 claims 1
- FVTHLZNPYMZQAF-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(dimethylamino)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(N(C)C)=C(NC(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 FVTHLZNPYMZQAF-UHFFFAOYSA-N 0.000 claims 1
- UYOFHFRQRGDMDB-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(CC(C)C)C(=O)C(CC)=C(NC(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 UYOFHFRQRGDMDB-UHFFFAOYSA-N 0.000 claims 1
- IHEGXROWEHIDPK-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(CC)=C(NC(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 IHEGXROWEHIDPK-UHFFFAOYSA-N 0.000 claims 1
- MUINCUOXHKQQBW-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-ethyl-1-methyl-2-oxo-1,8-naphthyridin-4-yl]butanamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)CCC)=C(CC)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl MUINCUOXHKQQBW-UHFFFAOYSA-N 0.000 claims 1
- BRJYGKRICFKEAO-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methoxy-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(OC)=C(NC(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 BRJYGKRICFKEAO-UHFFFAOYSA-N 0.000 claims 1
- YKHAVUBOYJSCEP-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]-2-methoxyacetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)COC)=C(C)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl YKHAVUBOYJSCEP-UHFFFAOYSA-N 0.000 claims 1
- YORGPZXVANKFJT-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]-n-methylacetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(N(C)C(C)=O)=C(C)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl YORGPZXVANKFJT-UHFFFAOYSA-N 0.000 claims 1
- WTXMJLGXZWLERW-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-1-(2-methylpropyl)-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(C)C(=O)N(CC(C)C)C2=NC=1C1=CC=C(Cl)C=C1Cl WTXMJLGXZWLERW-UHFFFAOYSA-N 0.000 claims 1
- FTQKKSQUMJSLIH-UHFFFAOYSA-N n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-methyl-2-oxo-1-propyl-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C=1C=C2C(NC(C)=O)=C(C)C(=O)N(CCC)C2=NC=1C1=CC=C(Cl)C=C1Cl FTQKKSQUMJSLIH-UHFFFAOYSA-N 0.000 claims 1
- QVWCUZKXJBMOGO-UHFFFAOYSA-N n-acetyl-n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-[(2,4-dimethoxyphenyl)methyl]-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)C=C(N(C(C)=O)C(C)=O)C2=CC(C=3C=CC(Cl)=CC=3)=C(C=3C(=CC(Cl)=CC=3)Cl)N=C21 QVWCUZKXJBMOGO-UHFFFAOYSA-N 0.000 claims 1
- BUEVOYHGXLTWRL-UHFFFAOYSA-N n-acetyl-n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-3-[methyl(propan-2-yl)amino]-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(N(C)C(C)C)=C(N(C(C)=O)C(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 BUEVOYHGXLTWRL-UHFFFAOYSA-N 0.000 claims 1
- CPPRNUOMAKZCHE-UHFFFAOYSA-N n-acetyl-n-[6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-3-(dimethylamino)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1C=1N=C2N(C)C(=O)C(N(C)C)=C(N(C(C)=O)C(C)=O)C2=CC=1C1=CC=C(Cl)C=C1 CPPRNUOMAKZCHE-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51706003P | 2003-11-04 | 2003-11-04 | |
| PCT/US2004/036102 WO2005047285A1 (en) | 2003-11-04 | 2004-10-29 | Substituted naphthyridinone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510649A JP2007510649A (ja) | 2007-04-26 |
| JP2007510649A5 true JP2007510649A5 (enExample) | 2007-08-09 |
Family
ID=34590136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538342A Pending JP2007510649A (ja) | 2003-11-04 | 2004-10-29 | 置換ナフチリジノン誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7728141B2 (enExample) |
| EP (1) | EP1682550B1 (enExample) |
| JP (1) | JP2007510649A (enExample) |
| CN (1) | CN1875021A (enExample) |
| AT (1) | ATE452890T1 (enExample) |
| AU (1) | AU2004289638B2 (enExample) |
| CA (1) | CA2544191A1 (enExample) |
| DE (1) | DE602004024814D1 (enExample) |
| WO (1) | WO2005047285A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1613318A4 (en) * | 2003-03-26 | 2009-03-11 | Bayer Pharmaceuticals Corp | COMPOUNDS AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISEASES |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| KR20070089151A (ko) | 2004-11-16 | 2007-08-30 | 지더블유 파마 리미티드 | 카나비노이드의 새로운 용도 |
| US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| CA2672656C (en) | 2006-12-18 | 2012-03-20 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| ES2393326T3 (es) | 2006-12-18 | 2012-12-20 | Amgen, Inc | Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| TW200838516A (en) * | 2007-01-31 | 2008-10-01 | Merck & Co Inc | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| WO2008118414A1 (en) * | 2007-03-28 | 2008-10-02 | Merck & Co., Inc. | Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators |
| EP2155680B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Indanone derivatives that inhibit prolyl hydroxylase |
| CA2683956C (en) | 2007-04-18 | 2012-12-18 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| EP2150251B9 (en) | 2007-05-04 | 2013-02-27 | Amgen, Inc | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| AU2008248165B2 (en) | 2007-05-04 | 2011-12-08 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
| EP2665741B1 (en) * | 2011-01-10 | 2019-03-06 | Invion, Inc | Use of beta-adrenergic inverse agonists for smoking cessation |
| WO2013067036A1 (en) * | 2011-10-31 | 2013-05-10 | Rutgers, The State University Of New Jersey | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| WO2013071698A1 (zh) * | 2011-11-17 | 2013-05-23 | 山东轩竹医药科技有限公司 | 三环类PI3K和/或mTOR抑制剂 |
| BR112020000962A2 (pt) * | 2017-07-18 | 2020-07-14 | Nuvation Bio Inc. | compostos de 1,8-naftiridinona e usos dos mesmos |
| MX2020000690A (es) | 2017-07-18 | 2020-07-29 | Nuvation Bio Inc | Compuestos heterociclicos como antagonistas de adenosina. |
| EP3911323A4 (en) | 2019-01-18 | 2022-11-16 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| US20230066315A1 (en) * | 2019-01-18 | 2023-03-02 | Nuvation Bio Inc. | Compounds and uses thereof |
| CA3126931A1 (en) * | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| IL297908A (en) | 2020-05-05 | 2023-01-01 | Teon Therapeutics Inc | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| WO1999002499A1 (en) | 1997-07-11 | 1999-01-21 | Japan Tobacco Inc. | Quinoline compounds and medicinal uses thereof |
| JP2000256323A (ja) * | 1999-01-08 | 2000-09-19 | Japan Tobacco Inc | ２−オキソキノリン化合物及びその医薬用途 |
| HUP0402310A2 (hu) * | 2001-09-26 | 2005-02-28 | Bayer Pharmaceuticals Corporation | 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények |
| TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
| WO2003086394A1 (en) * | 2002-04-08 | 2003-10-23 | Merck & Co., Inc. | Inhibitors of akt activity |
| EP1499306A4 (en) * | 2002-04-12 | 2007-03-28 | Merck & Co Inc | BICYCLIC AMIDE |
| ES2294330T3 (es) | 2002-08-02 | 2008-04-01 | MERCK & CO., INC. | Derivados de furo(2,3-b)piridina sustituidos. |
| SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
| SE0300908D0 (sv) | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| WO2005021547A2 (en) | 2003-08-28 | 2005-03-10 | Pharmaxis Pty Ltd. | Heterocyclic cannabinoid cb2 receptor antagonists |
| CA2541832C (en) | 2003-10-10 | 2009-11-24 | Pfizer Products Inc. | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
| WO2005049615A1 (en) | 2003-11-21 | 2005-06-02 | Pfizer Products Inc. | Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists |
| WO2005061505A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof |
| WO2005061504A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Bicyclic pyridazinone cannabinoid receptor ligands and uses thereof |
| WO2005061507A1 (en) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof |
| ES2282927T3 (es) * | 2003-12-19 | 2007-10-16 | Bristol-Myers Squibb Company | Heterociclos azabiciclicos como moduladores de receptores canabinoides. |
| US20060094714A1 (en) * | 2004-03-26 | 2006-05-04 | Bayer Pharmaceuticals Corporation | Compounds and their use to treat diabetes and related disorders |
| WO2005103052A1 (en) | 2004-04-21 | 2005-11-03 | Pfizer Products Inc. | Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof |
-
2004
- 2004-10-29 CA CA002544191A patent/CA2544191A1/en not_active Abandoned
- 2004-10-29 DE DE602004024814T patent/DE602004024814D1/de not_active Expired - Lifetime
- 2004-10-29 JP JP2006538342A patent/JP2007510649A/ja active Pending
- 2004-10-29 AU AU2004289638A patent/AU2004289638B2/en not_active Ceased
- 2004-10-29 WO PCT/US2004/036102 patent/WO2005047285A1/en not_active Ceased
- 2004-10-29 CN CNA2004800326528A patent/CN1875021A/zh active Pending
- 2004-10-29 AT AT04796813T patent/ATE452890T1/de not_active IP Right Cessation
- 2004-10-29 EP EP04796813A patent/EP1682550B1/en not_active Expired - Lifetime
- 2004-10-29 US US10/576,796 patent/US7728141B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007510649A5 (enExample) | ||
| JP7278359B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物および組成物 | |
| JP4180365B2 (ja) | ピペラジン誘導体 | |
| US10975080B2 (en) | Compounds and compositions for inhibiting the activity of SHP2 | |
| CN105143190B (zh) | 作为mao抑制剂的被取代的萘啶和喹啉化合物 | |
| JP2012526735A5 (enExample) | ||
| JP2012526736A5 (enExample) | ||
| TW202104223A (zh) | 磷脂醯肌醇3-激酶抑制劑 | |
| KR20010050223A (ko) | Ｃｒｆ 길항제 및 관련 조성물의 용도 | |
| TW201014849A (en) | 1,2-disubstituted heterocyclic compounds | |
| TW201201811A (en) | Heteroaryl imidazolone derivatives as JAK inhibitors | |
| RU2006114749A (ru) | Производные пиразоло- и имидазопиримидина | |
| KR20030042037A (ko) | 하지불안증후군에 대한 신규 치료법 | |
| JP2008510006A5 (enExample) | ||
| JP2008534568A5 (enExample) | ||
| JP2004526699A5 (enExample) | ||
| JP2022500466A (ja) | 抗ウイルス剤としての官能化複素環 | |
| SK9222003A3 (en) | Imidazolyl derivatives as corticotropin releasing factor inhibitors | |
| JP2021506868A (ja) | Ｐｄｅ１阻害剤としての大環状分子 | |
| CN117486890A (zh) | 三环类化合物及其用途 | |
| WO2008024151A2 (en) | Salts and co-crystals of pyrazolopyrimidine compounds, compositions thereof and methods for their production and use | |
| CA2868228C (en) | Treatment of respiratory depression | |
| WO2010053127A1 (ja) | α1GABAA受容体またはα5GABAA受容体の調整剤 | |
| KR20240134951A (ko) | 트립타민 조성물 및 방법 | |
| JP2004509869A5 (enExample) |